Patent Strategies and Competition Law in the Pharmaceutical Sector: Implications for Access to Medicines
661 - 667
European Intellectual Property Review
MetadataShow full item record
Potentially anti-competitive practices, such as reverse payment agreements and strategic patenting, risk allowing pharmaceutical companies to block the entry of generic and innovative medicines, stifling competition and harming consumers. Such practices create particular challenges for developing countries. Policy coherence between the IP system and competition law must be strengthened in order to promote innovation and access to health technologies.
AuthorsMATTHEWS, DN; Gurgula, O
- Department of Law 
Showing items related by title, author, creator and subject.
Chung, Shang-pei (Queen Mary University of London, 2012-10)The reconciliation of patents within the Taiwanese Law of Things has received negligible attention from legal scholars. The primary reason for this is the hesitation, by courts and scholars alike, to construct a new property ...
Gee, Lim Heng (1996)Prior to 1986, Malaysia had a system whereby patents issued in the United Kingdom could be registered in Malaysia. On registration, the patent owner would have privileges and rights as those conferred by the issue of ...
COMPULSORY LICENSING FOR PHARMACEUTICAL PATENTS: EXAMINING THE CONSISTENCY OF THE LOCAL WORKING REQUIREMENTS UNDER SECTION 84 OF THE INDIAN PATENT ACT WITH THE TRIPS AGREEMENT AS A MODEL FOR GHANA Manu, T (2019-05-03)Compulsory licensing would offer Ghana a practical means to mitigate the high costs and shortages of medicines resulting from the failure of patentees to work their patented medicines locally. Article 5(A) of the Paris ...